NB-64
| Code | Size | Price |
|---|
| TAR-T28133-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T28133-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T28133-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
NB-64 is a HIV-1 entry inhibitor. NB-64 interferes the gp41 six-helix bundle formation and blocks virus fusion.
CAS:
53242-68-5
Formula:
C11H8ClNO2
Molecular Weight:
221.64
Purity:
0.98
SMILES:
OC(=O)c1cc(ccc1Cl)-n1cccc1
References
1. Sepehri S, Saghaie L, Fassihi A. Anti-HIV-1 Activity Prediction of Novel Gp41 Inhibitors Using Structure-Based Virtual Screening and Molecular Dynamics Simulation. Mol Inform. 2017 Mar;36(3). doi: 10.1002/minf.201600060. Epub 2016 Oct 12. PubMed PMID: 27730744.
2. Sardari S, Azadmanesh K, Mahboudi F, Davood A, Vahabpour R, Zabihollahi R, Gomari H. Design of Small Molecules with HIV Fusion Inhibitory Property Based on Gp41 Interaction Assay. Avicenna J Med Biotechnol. 2013 Apr;5(2):78-86. PubMed PMID: 23799176; PubMed Central PMCID: PMC3689560.
3. Qadir MI, Malik SA. Genetic variation in the HR region of the env gene of HIV: A perspective for resistance to HIV fusion inhibitors. AIDS Res Hum Retroviruses. 2011 Jan;27(1):57-63. doi: 10.1089/aid.2010.0098. Epub 2010 Sep 28. PubMed PMID: 20874419.
4. Katritzky AR, Tala SR, Lu H, Vakulenko AV, Chen QY, Sivapackiam J, Pandya K, Jiang S, Debnath AK. Design, synthesis, and structure-activity relationship of a novel series of 2-aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 entry inhibitors. J Med Chem. 2009 Dec 10;52(23):7631-9. doi: 10.1021/jm900450n. PubMed PMID: 19746983; PubMed Central PMCID: PMC2802534.